30+ fellows & counting
30+ Years of the Lupus Ontario Geoff Carr Fellowship means, 30+ years of lupus research by our amazing fellows! Learn more about them below.
Fellow Spotlight!
Dr. Amanda Steiman
Assistant Professor, Rheumatologist at Sinai Health/University Health Network, Toronto
Dr. Amanda Steiman received the Fellowship in 2011. She is currently a staff rheumatologist at Sinai Health/University Health Network in Toronto, and an Assistant Professor of Medicine at the University of Toronto. Her clinical niche continues to be lupus, and she has developed a Young Adult SLE Clinic, in collaboration with pediatric rheumatologist/lupologist, Dr. Earl Silverman. Her academic interest is in Quality Improvement, and she continues to be involved in lupus research in this domain.
Dr. Steiman states,
‘The Geoff Carr Fellowship was invaluable to my current clinical and research activities, allowing me to hone my lupus acumen and develop my clinical and research foci, as above. It allowed me to work with world leaders in the field of lupus (Drs. Gladman and Urowitz).
Dr. Zahi Touma
Assistant Professor of Medicine, University of Toronto; Clinician Scientist, Krembil Research Institute
Dr. Zahi Touma was awarded the Fellowship in 2008 and 2010. He came to Canada from Lebanon. After his Fellowship years Dr. Touma stayed on as a Clinician-Scientist, Rheumatology, University Health Network. He continues to perform lupus research. He has completed many research projects.
Some of the key ones are:
- Improving the assessment of lupus disease activity – this resulted in the validation of SLEDAI-2K 30 days against 10 days; and the development of S2K RI-50 to measure partial improvement in disease activity
Development of a new tool to account for the dose of prednisone when assessing disease activity – SLEDAI 2KG - Validation of ANAM to facilitate cognitive function test in SLE patients
- Studying the role of LupusQoL – an SLE specific quality of life questionnaire
- Studying time to improvement of proteinuria in the management of lupus nephritis in addition to several studies focused on the prognostic value of proteinuria in term on other comorbidities (advanced chronic kidney disease, dialysis, etc.)
- ECG changes in SLE patients.
- Improving the assessment of anxiety and depression in SLE
Geoff Carr Fellowship Recipients
Meet all of the Lupus Ontario Geoff Carr Research fellows, and learn about their research and area of study!
Exploring racial disparities in disease-related activity and damage in SLE.
Therapeutic drug monitoring of HCQ is feasible in the cSLE population, allowing for individualized HCQ treatment with optimal efficacy and prevention of long- term toxicity.
Research focuses in neuropsychiatric (NPSLE), specifically examining the longitudinal prevalence of cognitive impairment and relationship to disease and health-related quality of life in cSLE.
Determination of the clinical subtypes of cognitive impairment in SLE patients to facilitate precision health care and better outcomes.
The potential role of serum HMGB1 from NETs as a biomarker to predict residual renal inflammation and subsequent flares in patients with lupus nephritis.
The potential role of serum HMGB1 from NETs as a biomarker to predict residual renal inflammation and subsequent flares in patients with lupus nephritis.
Prolonged antimalarial treatment may increase the risk for subclinical heart damage in systemic lupus erythematosus.
Depression in paediatric SLE patients.
Prolonged antimalarial treatment may increase the risk for subclinical heart damage in systemic lupus erythematosus.
The management of Arterial Hypertension and Hypercholesterolemia in patients with SLE. Are the current treatment guidelines adequate for lupus patients?
Pathophysiology of cognitive dysfunction in patients with antiphospholipid antibodies and lupus.
Cardio vascular risks in patients with SLE.
Predicting flares in patients who are serologically active and and clinically quiescent.
SRI-50 Index which is used to measure disease activity.
Lupus Nephritis.
Long term outcome of children with SLE with emphasis on the Central Nervous System
Outcome measures used in clinical trials in SLE in order to find an optimal measure.
Lupus Nephritis.
Atherscerlosis in SLE
Definition of thrombitis risk associated with anticardiolipin antibofy in SLE
Vascular disease in systemic Lupus Erythematosus
Methods to improve paediatric Lupus treatment.
Impact of the updated 1997 revised criteria for classification of SLE, Prolonged remission in SLE
The effective of menopause on disease activity in SLE
Bone mineral density in premenopausal females with SLE
Pathogenic mechanisms in lupus patients with CNS involvement
Assess the prevalence of ischemic heart disease in patients with SLE, current management of risk factors for coronary artery disease
Osteonecrosis in SLE
- Anticardiolipin Antibodies in SLE: Clinical and Laboratory Correlations
- The Significance of Anticardiolipin Antibodies in patients with Lupus Nephritis
Single Photon Emission Computerized Tomography (SPECT) in Neuropsychiatric SLE
- Prolactin in SLE
- Anti-neutrophil Cytoplasmic Antibodies (ANCA) in SLE
- Evaluation of predictive factors for neurocognitive dysfunction in patients with SLE
Serologically Active Clinically Quiescent Systemic Lupus Erythematosus (SLE) - Predictors of Clinical Flares